Type |
Details |
Score |
Strain |
Attribute String: |
coisogenic, endonuclease-mediated mutation, mutant strain |
|
•
•
•
•
•
|
Strain |
Attribute String: |
coisogenic, endonuclease-mediated mutation, mutant strain |
|
•
•
•
•
•
|
Allele |
Name: |
angiotensin converting enzyme 2; endonuclease-mediated mutation 2.1, Synbal |
Allele Type: |
Endonuclease-mediated |
Attribute String: |
Humanized sequence, Inserted expressed sequence, Null/knockout |
|
•
•
•
•
•
|
Allele |
Name: |
angiotensin converting enzyme 2; endonuclease-mediated mutation 1, Synbal |
Allele Type: |
Endonuclease-mediated |
Attribute String: |
Humanized sequence, Inserted expressed sequence, Null/knockout |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
805
|
Fragment?: |
false |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
265
|
Fragment?: |
true |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
521
|
Fragment?: |
true |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
557
|
Fragment?: |
true |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
787
|
Fragment?: |
true |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
805
|
Fragment?: |
false |
|
•
•
•
•
•
|
Strain |
Attribute String: |
congenic, mutant strain, targeted mutation, spontaneous mutation |
|
•
•
•
•
•
|
Publication |
First Author: |
Tseng CT |
Year: |
2007 |
Journal: |
J Virol |
Title: |
Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor. |
Volume: |
81 |
Issue: |
3 |
Pages: |
1162-73 |
|
•
•
•
•
•
|
Strain |
Attribute String: |
congenic, endonuclease-mediated mutation, mutant strain, transgenic, targeted mutation |
|
•
•
•
•
•
|
Strain |
Attribute String: |
endonuclease-mediated mutation, mutant strain |
|
•
•
•
•
•
|
Strain |
Attribute String: |
coisogenic, endonuclease-mediated mutation, mutant strain |
|
•
•
•
•
•
|
Protein Domain |
Type: |
Domain |
Description: |
The CoV Spike (S) protein is an envelope glycoprotein that plays the most important role in viral attachment, fusion, and entry into host cells, and serves as a major target for the development of neutralizing antibodies, inhibitors of viral entry, and vaccines. It is synthesised as a precursor protein that is cleaved into an N-terminal S1 subunit (~700 amino acids) and a C-terminal S2 subunit (~600 amino acids) that mediates attachment and membrane fusion, respectively. Three S1/S2 heterodimers assemble to form a trimer spike protruding from the viral envelope. The S1 subunit contains a receptor-binding domain (RBD), while the S2 subunit contains a hydrophobic fusion peptide and two heptad repeat regions. S1 contains two structurally independent domains, the N-terminal domain (NTD) and the C-terminal domain (C-domain). Depending on the virus, either the NTD or the C-domain can serve as the receptor-binding domain (RBD). Most CoVs, including SARS-CoV-2, SARS-CoV, and MERS-CoV use the C-domain to bind their receptors. However, CoV such as mouse hepatitis virus (MHV) uses the NTD to bind its receptor, mouse carcinoembryonic antigen related cell adhesion molecule 1a (mCEACAM1a). The S1 NTD contributes to the Spike trimer interface [, , , , ].This entry represents the RBD domain of Spike protein S1 subunit from SARS-CoV-2, which binds the extracellular peptidase domain of angiotensin-converting enzyme 2 (ACE2). It has been shown that the receptor binding induces the dissociation of the S1 with ACE2, prompting the S2 to transit from a metastable pre-fusion to a more-stable post-fusion state that is essential for membrane fusion [, , , ]. Recent structures revealed that only a single RBD is necessary for ACE2 binding and it is not yet clear if protrusion of the RBD from the S protein trimer is necessary for binding to ACE2 or the interconversion of the RBD between closed and open states represents an intrinsic property of the S protein []. During the pandemic, many amino acid substitutions have been reported in the S1 segment, being D614G the most commonly observed amino acid change from the reference sequence. Although it was estimated to be slightly destabilizing, it was hypothesized that it increases virus infectivity by increasing the total amount of S protein incorporated into virions. The most prevalent RBD substitution in the RBD is the T478I, located in a portion of a loop that contacts ACE2. However, most substitutions in the interface with ACE2 appear to be neutral or destabilizing, with none improving binding affinity [].SARS-CoV-2 RBD has a core formed by a twisted five-stranded antiparallel β-sheet (β1-7) with short helices and loops connecting them. Between the β4 and β7 strands in the core, there is an extended insertion, the receptor-binding motif (RBM), containing the short β5 and β6 strands, α4 and α5 helices and loops, which contains most of the contacting residues for binding to ACE2. There are nine cysteine residues in the RBD, eight of which form four pairs of disulfide bonds. Among these four pairs, three are in the core which help to stabilise the β-sheet structure, while the remaining pair connects the loops in the distal end of the RBM []. |
|
•
•
•
•
•
|
Publication |
First Author: |
Fraga-Silva RA |
Year: |
2008 |
Journal: |
Mol Med |
Title: |
The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets. |
Volume: |
14 |
Issue: |
1-2 |
Pages: |
28-35 |
|
•
•
•
•
•
|
Publication |
First Author: |
Ward K |
Year: |
1993 |
Journal: |
Nat Genet |
Title: |
A molecular variant of angiotensinogen associated with preeclampsia. |
Volume: |
4 |
Issue: |
1 |
Pages: |
59-61 |
|
•
•
•
•
•
|
Publication |
First Author: |
Donoghue M |
Year: |
2000 |
Journal: |
Circ Res |
Title: |
A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. |
Volume: |
87 |
Issue: |
5 |
Pages: |
E1-9 |
|
•
•
•
•
•
|
Publication |
First Author: |
Ehlers MR |
Year: |
1989 |
Journal: |
Biochemistry |
Title: |
Angiotensin-converting enzyme: new concepts concerning its biological role. |
Volume: |
28 |
Issue: |
13 |
Pages: |
5311-8 |
|
•
•
•
•
•
|
Publication |
First Author: |
Fuchs S |
Year: |
2004 |
Journal: |
Curr Hypertens Rep |
Title: |
Newly recognized physiologic and pathophysiologic actions of the angiotensin-converting enzyme. |
Volume: |
6 |
Issue: |
2 |
Pages: |
124-8 |
|
•
•
•
•
•
|
Publication |
First Author: |
Goodfriend TL |
Year: |
1975 |
Journal: |
Circ Res |
Title: |
Angiotensin III: (DES-Aspartic Acid-1)-Angiotensin II. Evidence and speculation for its role as an important agonist in the renin - angiotensin system. |
Volume: |
36 |
Issue: |
6 Suppl 1 |
Pages: |
38-48 |
|
•
•
•
•
•
|
Publication |
First Author: |
Flohr H |
Year: |
1975 |
Journal: |
Arzneimittelforschung |
Title: |
Effect of etafenone on total and regional myocardial blood flow. |
Volume: |
25 |
Issue: |
9 |
Pages: |
1400-3 |
|
•
•
•
•
•
|
Publication |
First Author: |
Marniemi J |
Year: |
1975 |
Journal: |
Biochem Pharmacol |
Title: |
Radiochemical assay of glutathione S-epoxide transferase and its enhancement by phenobarbital in rat liver in vivo. |
Volume: |
24 |
Issue: |
17 |
Pages: |
1569-72 |
|
•
•
•
•
•
|
Publication |
First Author: |
Agardh CD |
Year: |
1979 |
Journal: |
Diabetes |
Title: |
The effect of pronounced hypoglycemia on monoamine metabolism in rat brain. |
Volume: |
28 |
Issue: |
9 |
Pages: |
804-9 |
|
•
•
•
•
•
|
Publication |
First Author: |
Lewis J |
Year: |
1976 |
Journal: |
J Stud Alcohol |
Title: |
Washington report. |
Volume: |
37 |
Issue: |
3 |
Pages: |
409-14 |
|
•
•
•
•
•
|
Protein Domain |
Type: |
Family |
Description: |
Angiotensinogen is a component of the renin-angiotensin system (RAS), a hormone system that regulates blood pressure and fluid balance. It is also known as the renin substrate, and is a non-inhibitory member of the serpin family of proteinase inhibitors (MEROPS inhibitor family I4, clan ID, MEROPS identifier I04.953).Angiotensinogen is catalytically cleaved by renin to produce angiotensin I in response to lowered blood pressure. Angiotensin converting enzyme (ACE), subsequently removes a dipeptide to produce angiotensin II, the physiologically active peptide, which functions in the regulation of volume and mineral balance of body fluids [, ]. Angiotensin I and angiotensin II can be further processed to generate angiotensin III, which stimulates aldosterone release [], and angiotensin IV. Angiotensin 1-9 is cleaved from angiotensin-1 by ACE2 []and can be further processed by ACE to produce angiotensin 1-7, angiotensin 1-5 and angiotensin 1-4 [, ].Angiotensinogen is synthesised in the liver and secreted in plasma [, , , ]. Angiotensinogen appears to be associated with a predisposition to essential hypertension; it is also associated with pregnancy-induced hypertension (pih) (preeclampsia), a heterogeneous disorder that complicates 5-7% of all pregnancies and remains a leading cause of maternal, foetal and neonatal morbidity and mortality [].The entry represents the full precursor sequence of angiotensinogen. |
|
•
•
•
•
•
|
Protein Domain |
Type: |
Domain |
Description: |
Angiotensinogen is a component of the renin-angiotensin system (RAS), a hormone system that regulates blood pressure and fluid balance. It is also known as the renin substrate, and is a non-inhibitory member of the serpin family of proteinase inhibitors (MEROPS inhibitor family I4, clan ID, MEROPS identifier I04.953).Angiotensinogen is catalytically cleaved by renin to produce angiotensin I in response to lowered blood pressure. Angiotensin converting enzyme (ACE), subsequently removes a dipeptide to produce angiotensin II, the physiologically active peptide, which functions in the regulation of volume and mineral balance of body fluids [, ]. Angiotensin I and angiotensin II can be further processed to generate angiotensin III, which stimulates aldosterone release [], and angiotensin IV. Angiotensin 1-9 is cleaved from angiotensin-1 by ACE2 []and can be further processed by ACE to produce angiotensin 1-7, angiotensin 1-5 and angiotensin 1-4 [, ].Angiotensinogen is synthesised in the liver and secreted in plasma [, , , ]. Angiotensinogen appears to be associated with a predisposition to essential hypertension; it is also associated with pregnancy-induced hypertension (pih) (preeclampsia), a heterogeneous disorder that complicates 5-7% of all pregnancies and remains a leading cause of maternal, foetal and neonatal morbidity and mortality [].This entry represents the serpin domain of angiotensinogen. |
|
•
•
•
•
•
|
Publication |
First Author: |
Kowalczuk S |
Year: |
2008 |
Journal: |
FASEB J |
Title: |
A protein complex in the brush-border membrane explains a Hartnup disorder allele. |
Volume: |
22 |
Issue: |
8 |
Pages: |
2880-7 |
|
•
•
•
•
•
|
Publication |
First Author: |
Fairweather SJ |
Year: |
2015 |
Journal: |
J Biol Chem |
Title: |
Molecular basis for the interaction of the mammalian amino acid transporters B0AT1 and B0AT3 with their ancillary protein collectrin. |
Volume: |
290 |
Issue: |
40 |
Pages: |
24308-25 |
|
•
•
•
•
•
|
Publication |
First Author: |
Danilczyk U |
Year: |
2006 |
Journal: |
Nature |
Title: |
Essential role for collectrin in renal amino acid transport. |
Volume: |
444 |
Issue: |
7122 |
Pages: |
1088-91 |
|
•
•
•
•
•
|
Publication |
First Author: |
Hassan AO |
Year: |
2020 |
Journal: |
Cell |
Title: |
A SARS-CoV-2 Infection Model in Mice Demonstrates Protection by Neutralizing Antibodies. |
|
|
|
|
•
•
•
•
•
|
Publication |
First Author: |
Spalinger MR |
Year: |
2020 |
Journal: |
bioRxiv |
Title: |
Identification of a Novel Susceptibility Marker for SARS-CoV-2 Infection in Human Subjects and Risk Mitigation with a Clinically Approved JAK Inhibitor in Human/Mouse Cells. |
|
|
|
|
•
•
•
•
•
|
Publication |
First Author: |
Jennewein MF |
Year: |
2021 |
Journal: |
Cell Rep |
Title: |
Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. |
Volume: |
36 |
Issue: |
2 |
Pages: |
109353 |
|
•
•
•
•
•
|
Publication |
First Author: |
Iwanaga N |
Year: |
2022 |
Journal: |
iScience |
Title: |
ACE2-IgG1 fusions with improved in vitro and in vivo activity against SARS-CoV-2. |
Volume: |
25 |
Issue: |
1 |
Pages: |
103670 |
|
•
•
•
•
•
|
Publication |
First Author: |
Joyce MG |
Year: |
2021 |
Journal: |
Cell Rep |
Title: |
SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. |
Volume: |
37 |
Issue: |
12 |
Pages: |
110143 |
|
•
•
•
•
•
|
Publication |
First Author: |
Stolp B |
Year: |
2022 |
Journal: |
Cell Rep |
Title: |
SARS-CoV-2 variants of concern display enhanced intrinsic pathogenic properties and expanded organ tropism in mouse models. |
Volume: |
38 |
Issue: |
7 |
Pages: |
110387 |
|
•
•
•
•
•
|
Publication |
First Author: |
Robertson SJ |
Year: |
2023 |
Journal: |
Nat Commun |
Title: |
Genetically diverse mouse models of SARS-CoV-2 infection reproduce clinical variation in type I interferon and cytokine responses in COVID-19. |
Volume: |
14 |
Issue: |
1 |
Pages: |
4481 |
|
•
•
•
•
•
|
Publication |
First Author: |
Parray HA |
Year: |
2022 |
Journal: |
PLoS Pathog |
Title: |
A broadly neutralizing monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV-2 variants of concern. |
Volume: |
18 |
Issue: |
12 |
Pages: |
e1010994 |
|
•
•
•
•
•
|
Publication |
First Author: |
Appelberg S |
Year: |
2022 |
Journal: |
EMBO Mol Med |
Title: |
A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells. |
Volume: |
14 |
Issue: |
10 |
Pages: |
e15821 |
|
•
•
•
•
•
|
Publication |
First Author: |
Wu CT |
Year: |
2023 |
Journal: |
Cell |
Title: |
SARS-CoV-2 replication in airway epithelia requires motile cilia and microvillar reprogramming. |
Volume: |
186 |
Issue: |
1 |
Pages: |
112-130.e20 |
|
•
•
•
•
•
|
Publication |
First Author: |
Song E |
Year: |
2021 |
Journal: |
J Exp Med |
Title: |
Neuroinvasion of SARS-CoV-2 in human and mouse brain. |
Volume: |
218 |
Issue: |
3 |
|
|
•
•
•
•
•
|
Publication |
First Author: |
Hedges JF |
Year: |
2022 |
Journal: |
Front Immunol |
Title: |
An ADAM17-Neutralizing Antibody Reduces Inflammation and Mortality While Increasing Viral Burden in a COVID-19 Mouse Model. |
Volume: |
13 |
|
Pages: |
918881 |
|
•
•
•
•
•
|
Publication |
First Author: |
Chong Z |
Year: |
2022 |
Journal: |
Cell Rep |
Title: |
Nasally delivered interferon-λ protects mice against infection by SARS-CoV-2 variants including Omicron. |
Volume: |
39 |
Issue: |
6 |
Pages: |
110799 |
|
•
•
•
•
•
|
Publication |
First Author: |
Chen IP |
Year: |
2022 |
Journal: |
Cell Rep |
Title: |
Viral E protein neutralizes BET protein-mediated post-entry antagonism of SARS-CoV-2. |
Volume: |
40 |
Issue: |
3 |
Pages: |
111088 |
|
•
•
•
•
•
|
Publication |
First Author: |
Case JB |
Year: |
2020 |
Journal: |
Cell Host Microbe |
Title: |
Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice. |
Volume: |
28 |
Issue: |
3 |
Pages: |
465-474.e4 |
|
•
•
•
•
•
|
Publication |
First Author: |
Oladunni FS |
Year: |
2020 |
Journal: |
Nat Commun |
Title: |
Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice. |
Volume: |
11 |
Issue: |
1 |
Pages: |
6122 |
|
•
•
•
•
•
|
Publication |
First Author: |
Ye G |
Year: |
2021 |
Journal: |
Elife |
Title: |
The development of Nanosota-1 as anti-SARS-CoV-2 nanobody drug candidates. |
Volume: |
10 |
|
|
|
•
•
•
•
•
|
Publication |
First Author: |
Konrath KM |
Year: |
2022 |
Journal: |
Cell Rep |
Title: |
Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection. |
Volume: |
38 |
Issue: |
5 |
Pages: |
110318 |
|
•
•
•
•
•
|
Publication |
First Author: |
Bertoglio F |
Year: |
2021 |
Journal: |
Cell Rep |
Title: |
A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. |
Volume: |
36 |
Issue: |
4 |
Pages: |
109433 |
|
•
•
•
•
•
|
Publication |
First Author: |
Bishop CR |
Year: |
2022 |
Journal: |
PLoS Pathog |
Title: |
Mouse models of COVID-19 recapitulate inflammatory pathways rather than gene expression. |
Volume: |
18 |
Issue: |
9 |
Pages: |
e1010867 |
|
•
•
•
•
•
|
Publication |
First Author: |
Belouzard S |
Year: |
2022 |
Journal: |
PLoS Pathog |
Title: |
Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice. |
Volume: |
18 |
Issue: |
5 |
Pages: |
e1010498 |
|
•
•
•
•
•
|
Publication |
First Author: |
Bishop CR |
Year: |
2022 |
Journal: |
bioRxiv |
Title: |
Mouse models of COVID-19 recapitulate inflammatory pathways rather than gene expression. |
|
|
|
|
•
•
•
•
•
|
Publication |
First Author: |
Ding S |
Year: |
2022 |
Journal: |
iScience |
Title: |
VE607 stabilizes SARS-CoV-2 Spike in the "RBD-up" conformation and inhibits viral entry. |
Volume: |
25 |
Issue: |
7 |
Pages: |
104528 |
|
•
•
•
•
•
|
Publication |
First Author: |
Mills RJ |
Year: |
2021 |
Journal: |
Cell |
Title: |
BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. |
Volume: |
184 |
Issue: |
8 |
Pages: |
2167-2182.e22 |
|
•
•
•
•
•
|
Publication |
First Author: |
Biering SB |
Year: |
2022 |
Journal: |
Nat Commun |
Title: |
SARS-CoV-2 Spike triggers barrier dysfunction and vascular leak via integrins and TGF-β signaling. |
Volume: |
13 |
Issue: |
1 |
Pages: |
7630 |
|
•
•
•
•
•
|
Publication |
First Author: |
Joag V |
Year: |
2021 |
Journal: |
J Immunol |
Title: |
Cutting Edge: Mouse SARS-CoV-2 Epitope Reveals Infection and Vaccine-Elicited CD8 T Cell Responses. |
Volume: |
206 |
Issue: |
5 |
Pages: |
931-935 |
|
•
•
•
•
•
|
Publication |
First Author: |
Chen Y |
Year: |
2023 |
Journal: |
iScience |
Title: |
Molecular basis for antiviral activity of two pediatric neutralizing antibodies targeting SARS-CoV-2 Spike RBD. |
Volume: |
26 |
Issue: |
1 |
Pages: |
105783 |
|
•
•
•
•
•
|
Publication |
First Author: |
Abdelfattah AS |
Year: |
2023 |
Journal: |
Neuron |
Title: |
Sensitivity optimization of a rhodopsin-based fluorescent voltage indicator. |
Volume: |
111 |
Issue: |
10 |
Pages: |
1547-1563.e9 |
|
•
•
•
•
•
|
Publication |
First Author: |
Biering SB |
Year: |
2022 |
Journal: |
Nat Genet |
Title: |
Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection. |
Volume: |
54 |
Issue: |
8 |
Pages: |
1078-1089 |
|
•
•
•
•
•
|
Publication |
First Author: |
Sun J |
Year: |
2020 |
Journal: |
Cell |
Title: |
Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment. |
Volume: |
182 |
Issue: |
3 |
Pages: |
734-743.e5 |
|
•
•
•
•
•
|
Publication |
First Author: |
Sajuthi SP |
Year: |
2020 |
Journal: |
bioRxiv |
Title: |
Type 2 and interferon inflammation strongly regulate SARS-CoV-2 related gene expression in the airway epithelium. |
|
|
|
|
•
•
•
•
•
|
Publication |
First Author: |
Lei C |
Year: |
2020 |
Journal: |
Nat Commun |
Title: |
Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig. |
Volume: |
11 |
Issue: |
1 |
Pages: |
2070 |
|
•
•
•
•
•
|
Publication |
First Author: |
Fougeroux C |
Year: |
2021 |
Journal: |
Nat Commun |
Title: |
Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. |
Volume: |
12 |
Issue: |
1 |
Pages: |
324 |
|
•
•
•
•
•
|
Publication |
First Author: |
Du S |
Year: |
2020 |
Journal: |
Cell |
Title: |
Structurally Resolved SARS-CoV-2 Antibody Shows High Efficacy in Severely Infected Hamsters and Provides a Potent Cocktail Pairing Strategy. |
Volume: |
183 |
Issue: |
4 |
Pages: |
1013-1023.e13 |
|
•
•
•
•
•
|
Publication |
First Author: |
Fodoulian L |
Year: |
2020 |
Journal: |
iScience |
Title: |
SARS-CoV-2 Receptors and Entry Genes Are Expressed in the Human Olfactory Neuroepithelium and Brain. |
Volume: |
23 |
Issue: |
12 |
Pages: |
101839 |
|
•
•
•
•
•
|
Publication |
First Author: |
Zhuang X |
Year: |
2021 |
Journal: |
bioRxiv |
Title: |
The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells. |
|
|
|
|
•
•
•
•
•
|
Publication |
First Author: |
Yamaguchi T |
Year: |
2021 |
Journal: |
Nat Commun |
Title: |
ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury. |
Volume: |
12 |
Issue: |
1 |
Pages: |
6791 |
|
•
•
•
•
•
|
Publication |
First Author: |
Sefik E |
Year: |
2022 |
Journal: |
Nat Biotechnol |
Title: |
A humanized mouse model of chronic COVID-19. |
Volume: |
40 |
Issue: |
6 |
Pages: |
906-920 |
|
•
•
•
•
•
|
Publication |
First Author: |
Zhuang X |
Year: |
2021 |
Journal: |
iScience |
Title: |
The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells. |
Volume: |
24 |
Issue: |
10 |
Pages: |
103144 |
|
•
•
•
•
•
|
Publication |
First Author: |
Almanza G |
Year: |
2021 |
Journal: |
bioRxiv |
Title: |
Structure-selected RBM immunogens prime polyclonal memory response that neutralize SARS-CoV-2 variants of concern. |
|
|
|
|
•
•
•
•
•
|
Publication |
First Author: |
Du W |
Year: |
2022 |
Journal: |
bioRxiv |
Title: |
An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants. |
|
|
|
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
1312
|
Fragment?: |
false |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
737
|
Fragment?: |
false |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
1312
|
Fragment?: |
false |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
1016
|
Fragment?: |
true |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
275
|
Fragment?: |
true |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
1015
|
Fragment?: |
true |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
1187
|
Fragment?: |
true |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
157
|
Fragment?: |
true |
|
•
•
•
•
•
|
Protein |
Organism: |
Mus musculus/domesticus |
Length: |
1312
|
Fragment?: |
false |
|
•
•
•
•
•
|
Publication |
First Author: |
Isaac RE |
Year: |
1998 |
Journal: |
Ann N Y Acad Sci |
Title: |
Toward a role for angiotensin-converting enzyme in insects. |
Volume: |
839 |
|
Pages: |
288-92 |
|
•
•
•
•
•
|
Publication |
First Author: |
Wei L |
Year: |
1991 |
Journal: |
J Biol Chem |
Title: |
The two homologous domains of human angiotensin I-converting enzyme are both catalytically active. |
Volume: |
266 |
Issue: |
14 |
Pages: |
9002-8 |
|
•
•
•
•
•
|
Publication |
First Author: |
Kim HM |
Year: |
2003 |
Journal: |
FEBS Lett |
Title: |
Crystal structure of Drosophila angiotensin I-converting enzyme bound to captopril and lisinopril. |
Volume: |
538 |
Issue: |
1-3 |
Pages: |
65-70 |
|
•
•
•
•
•
|
Publication |
First Author: |
Corradi HR |
Year: |
2007 |
Journal: |
Biochemistry |
Title: |
The structure of testis angiotensin-converting enzyme in complex with the C domain-specific inhibitor RXPA380. |
Volume: |
46 |
Issue: |
18 |
Pages: |
5473-8 |
|
•
•
•
•
•
|
Publication |
First Author: |
Watermeyer JM |
Year: |
2008 |
Journal: |
Biochemistry |
Title: |
Probing the basis of domain-dependent inhibition using novel ketone inhibitors of Angiotensin-converting enzyme. |
Volume: |
47 |
Issue: |
22 |
Pages: |
5942-50 |
|
•
•
•
•
•
|
Protein Domain |
Type: |
Family |
Description: |
This group of metallopeptidases belong to the MEROPS peptidase family M2 (clan MA(E)). The protein fold of the peptidase domain for members of this family resembles that of thermolysin, the type example for clan MA. The catalytic residues and zinc ligands have been identified, the zinc ion being ligated to two His residues within the motif HEXXH, showing that the enzyme belongs to the glu-zincin sub-group of metalloproteases [].Peptidyl-dipeptidase A (angiotensin-converting enzyme or ACE, ) is a mammalian enzyme responsible for cleavage of dipeptides from the C-termini of proteins, notably converting decapeptide angiotensin I to the octapeptide angiotensin II []. The enzyme exists in two differentially transcribed forms, the most common of which is from lung endothelium; this contains two homologous domains that have arisen by gene duplication []. The testis-specific form contains only the C-terminal domain, arising from a duplicated promoter region present in intron 12 of the gene []. Both enzymatic forms are membrane proteins that are anchored by means of a C-terminal transmembrane domain. Both domains of the endothelial enzyme are active, but have differing kinetic constants [, ]. ACE is well-known as a key part of the renin-angiotensin system that regulates blood pressure and ACE inhibitors are important for the treatment of hypertension [, ].An ACE homologue, ACE2 (MEROPS identifier M02.006), has been identified in humans that differs from ACE; it preferentially removes carboxy-terminal hydrophobic or basic amino acids and appears to be important in cardiac function [, ]. ACE3 is a non-peptidase homologue included in this entry which lacks Glu378 in the HEXXH motif.A number of insect enzymes have been shown to be similar to peptidyl-dipeptidase A, these containing a single catalytic domain [, ]. |
|
•
•
•
•
•
|
Publication |
First Author: |
Zumla A |
Year: |
2016 |
Journal: |
Nat Rev Drug Discov |
Title: |
Coronaviruses - drug discovery and therapeutic options. |
Volume: |
15 |
Issue: |
5 |
Pages: |
327-47 |
|
•
•
•
•
•
|
Publication |
First Author: |
Castanheira FVS |
Year: |
2023 |
Journal: |
Blood Adv |
Title: |
Intravital imaging of three different microvascular beds in SARS-CoV-2-infected mice. |
Volume: |
7 |
Issue: |
15 |
Pages: |
4170-4181 |
|
•
•
•
•
•
|
Publication |
First Author: |
Wrapp D |
Year: |
2020 |
Journal: |
Science |
Title: |
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. |
Volume: |
367 |
Issue: |
6483 |
Pages: |
1260-1263 |
|
•
•
•
•
•
|
Publication |
First Author: |
Yan R |
Year: |
2020 |
Journal: |
Science |
Title: |
Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. |
Volume: |
367 |
Issue: |
6485 |
Pages: |
1444-1448 |
|
•
•
•
•
•
|
Publication |
First Author: |
Gretebeck LM |
Year: |
2015 |
Journal: |
Curr Opin Virol |
Title: |
Animal models for SARS and MERS coronaviruses. |
Volume: |
13 |
|
Pages: |
123-9 |
|
•
•
•
•
•
|
Strain |
Attribute String: |
coisogenic, endonuclease-mediated mutation, mutant strain |
|
•
•
•
•
•
|
Strain |
Attribute String: |
endonuclease-mediated mutation, mutant strain |
|
•
•
•
•
•
|
Publication |
First Author: |
Shang J |
Year: |
2020 |
Journal: |
Nature |
Title: |
Structural basis of receptor recognition by SARS-CoV-2. |
Volume: |
581 |
Issue: |
7807 |
Pages: |
221-224 |
|
•
•
•
•
•
|
Publication |
First Author: |
Sato T |
Year: |
2017 |
Journal: |
Cardiovasc Res |
Title: |
ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage. |
Volume: |
113 |
Issue: |
7 |
Pages: |
760-769 |
|
•
•
•
•
•
|
Publication |
First Author: |
Strine MS |
Year: |
2023 |
Journal: |
PLoS Biol |
Title: |
DYRK1A promotes viral entry of highly pathogenic human coronaviruses in a kinase-independent manner. |
Volume: |
21 |
Issue: |
6 |
Pages: |
e3002097 |
|
•
•
•
•
•
|
Publication |
First Author: |
Zheng J |
Year: |
2014 |
Journal: |
Neuroscience |
Title: |
Activation of the ACE2/Ang-(1-7)/Mas pathway reduces oxygen-glucose deprivation-induced tissue swelling, ROS production, and cell death in mouse brain with angiotensin II overproduction. |
Volume: |
273 |
|
Pages: |
39-51 |
|
•
•
•
•
•
|
Publication |
First Author: |
Guimarães GG |
Year: |
2012 |
Journal: |
Peptides |
Title: |
Exercise induces renin-angiotensin system unbalance and high collagen expression in the heart of Mas-deficient mice. |
Volume: |
38 |
Issue: |
1 |
Pages: |
54-61 |
|
•
•
•
•
•
|
Publication |
First Author: |
Wang W |
Year: |
2019 |
Journal: |
Proc Natl Acad Sci U S A |
Title: |
Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs. |
Volume: |
116 |
Issue: |
26 |
Pages: |
13006-13015 |
|
•
•
•
•
•
|